Analyse court terme - CELGENE CORP : Pull-back
La tendance est momentanément interrompue par une correction. Elle approche de la résistance à 97,50 $, qui est également le niveau d'invalidation. Ceci pourrait relancer le mouvement baissier. Le prochain objectif est à 83,10 $. Le niveau d'invalidation est au-dessus de 97,50 $.Arguments :
- Les cours font un pull-back sur la résistance majeure (ancien support), la baisse reprendra ensuite.
- La moyenne mobile sert de résistance.
- Le gap a été testé, la tendance baissière peut reprendre.
Celgene is a global biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The company's primary commercial stage products include: REVLIMID?, an oral immunomodulatory drug; POMALYST?/IMNOVID?, a proprietary, small molecule; OTEZLA?, an oral small-molecule inhibitor of phosphodiesterase 4 for cyclic adenosine monophosphate; ABRAXANE?, a solvent-free chemotherapy product; and VIDAZA?, a pyrimidine nucleoside analog. In addition, the company provides other product sales and licensing arrangements.
DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.